Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1994-07-22
1996-09-03
Jordan, Kimberly
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514170, 514182, 514843, A61K 3156
Patent
active
055523943
ABSTRACT:
A method of female contraception which is characterized by a reduced incidence of breakthrough bleeding after the first cycle involves monophasicly administering a combination of estrogen and progestin for 23-25 consecutive days of a 28 day cycle in which the daily amounts of estrogen and progestin are equivalent to about 5-35 mcg of ethinyl estradiol and about 0.025 to 10 mg of norethindrone acetate, respectively and in which the weight ratio of estrogen to progestin is at least 1:45 calculated as ethinyl estradiol to norethindrone acetate.
REFERENCES:
patent: 3932635 (1976-01-01), Segre
patent: 5010070 (1991-04-01), Boissonneault
patent: 5098714 (1992-03-01), Wright
patent: 5262408 (1993-11-01), Bergink
CA 76:30782, Craft et al., 1971.
Martindale, The Extra Pharmacopoeia, Edited by James E. F. Reynolds, pp. 2003-2004, Thirtieth Edition. (1993).
AHFS Drug Information 33, p. 2348. (1993).
Drug Information for the Health Care Professional, vol. 1, USP DI 1993, 13th Edition, Chapter 50.
Jordan Kimberly
The Medical College of Hampton Roads
LandOfFree
Low dose oral contraceptives with less breakthrough bleeding and does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Low dose oral contraceptives with less breakthrough bleeding and, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Low dose oral contraceptives with less breakthrough bleeding and will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1950014